BioMed Nexus Daily Updates brings you the latest breakthroughs, trends, and news in Biotech, MedTech, and Pharma—delivered fresh every day. From cutting-edge innovations to industry shifts, our concise recaps keep you ahead in a fast-moving field. Join 20,000+ subscribers.
Biotech opened the week navigating extreme regulatory volatility and clinical performance divergence. uniQure suffered a devastating 49% share collapse after the FDA reversed course on
Healthcare markets exploded with deal-making activity as November opened with a bang. Novartis dropped $12 billion to acquire Avidity Biosciences, Novo Nordisk and Pfizer escalated
Biotech delivered a sobering Halloween eve session as regulatory concerns collided with policy reforms and M&A speculation. Intellia Therapeutics’ CRISPR programs hit an FDA clinical
Healthcare markets delivered a news-heavy session today as mega-deals, regulatory shifts, and compelling clinical data converged to reshape sector dynamics. Thermo Fisher Scientific’s $8.9 billion
Monday delivered a mixed but ultimately positive session for healthcare investors, with strong pharmaceutical earnings and strategic deals offsetting concerns about biotech funding headwinds. Biopharma
The healthcare sector delivered a remarkable week of innovation, deal-making, and regulatory transformation. From the FDA’s groundbreaking National Priority Review program to over $6.4 billion
Explore the latest biotech innovations from October 6-13, 2025: AstraZeneca’s oncology trials, FDA approvals for IPF and CSCC, allogeneic CAR-NK cells, and trends in direct-to-consumer
Genmab acquires Merus for $8B, FDA approves Alzheimer’s blood test, and Trump Administration secures drug pricing deals. Complete biotech industry analysis. 1. Genmab’s $8 Billion
The final week of September brought seismic shifts across the pharmaceutical and biotechnology sectors, with an $8 billion oncology acquisition, leadership changes at Big Pharma
The pharmaceutical industry’s marketing playbook is about to get a major rewrite. The FDA has announced an aggressive campaign against misleading drug advertisements, signaling the
